AIM:To evaluate the clinical effect of subconjunctival injection of triamcinolone acetonide in patients with macular edema secondary to uveitis.

METHODS:Sixty-eight patients(82 eyes)with macular edema secondary to uveitis selected in our hospital from October 2014 to October 2015 were assigned into control group and experimental group according to random number table method, with 34 cases(41 eyes)in each group. Patients in the control group were treated by intraocular injection of triamcinolone acetonide, and patients in the experimental group were given subconjunctival injection of triamcinolone acetonide. Clinical effect, central macular thickness and adverse reactions in the two groups were compared.

RESULTS:There was no significant difference on the central macular thickness and best corrected visual acuity between the two groups before treatment(P>0.05). Central macular thickness in the experimental group after treatment(214.26±65.54 μm)was significantly lower than that in the control group after treatment(256.47±84.52 μm,P<0.05), and best corrected visual acuity in the experimental group after treatment(4.8±1.3)was significantly higher than that in the control group(4.0±1.4, P<0.05). The overall response rate in the observation group(98%)was obviously higher than that in the control group(83%, P<0.05). The incidence of adverse reactions in the observation group(37%)was significantly lower than that in the control group after treatment(59%, P<0.05).

CONCLUSION:Subconjunctival injection of triamcinolone acetonide exerts obvious effect in uveitis patients with macular edema, effectively improves visual acuity, alleviates macular edema and reduces the incidence of intraocular pressure increasing, conjunctival hemorrhage and other adverse reactions, which is safe and effective, thus has potential application.